Articles related to LUNG CANCER

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.

This approval was based on findings from the open-label, randomized, multicenter POSEIDON trial, which compared data from two of the study’s three treatment arms. When compared to patients in the other treatment arm, patients in this group had a significantly improved OS, with a median OS of 14 months as opposed to 11.7 months.

Neoadjuvant nivolumab plus chemotherapy improved event-free survival and increased the proportion of patients who had a pathological complete response in patients with resectable NSCLC compared to chemotherapy alone. Nivolumab was added to neoadjuvant chemotherapy, but neither the incidence of side effects nor the viability of surgery was affected.

A Narrative Review Liquid biopsy is increasingly being used clinically in advanced lung cancer, according to this review, and ongoing research is identifying applications of circulating tumor DNA-based testing that complement tissue analysis across a wide range of clinical settings. At many stages of the patient’s oncologic journey, circulating tumor DNA technologies are demonstrating potential benefits for patients, health care practitioners, health care systems, and researchers.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.

Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRASinhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led tolower rates of grade 3-4 treatment-related adverse events compared with beginningadministration of the treatments concurrently.